Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

This study has been terminated.
(recruitment goals met)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00148135
First received: September 2, 2005
Last updated: December 28, 2007
Last verified: December 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2007
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)